Citi attributes the selloff yesterday in the shares of Ideaya Biosciences (IDYA) to profit taking post the company’s research and development day. The firm views the pullback as overdone and keeps a Buy rating on the shares with a $64 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences: Promising Pipeline and Clinical Advancements Drive Buy Rating
- Ideaya Biosciences price target lowered to $36 from $37 at Oppenheimer
- Ideaya Biosciences to present initial data from Phase 1/2 trial of IDE397
- IDEAYA Biosciences: Strong Buy Rating Backed by Promising Oncology Pipeline and Positive Phase 1 Data for IDE849
- IDEAYA Biosciences Reports Promising Phase 1 Data for IDE849